Piper Sandler Maintains Neutral on Enfusion, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Sumeet Mody has maintained a Neutral rating on Enfusion (NYSE:ENFN) and increased the price target from $9 to $10.

December 20, 2023 | 7:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained a Neutral rating on Enfusion but raised the price target from $9 to $10, indicating a positive outlook on the stock's value.
The increase in price target by Piper Sandler suggests a positive reassessment of Enfusion's stock value, which could lead to increased investor confidence and a potential short-term rise in the stock price. The Neutral rating indicates that the analyst does not see significant overperformance or underperformance in the near term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100